Seattle, Wash, July 17, 2014 – Ruth McBride, Scientific Director at Axio Research, co–authored a Letter to the Editor published in the New England Journal of Medicine entitled “Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial”. In the letter, the investigators present the rates of serious adverse events in the AIM–HIGH trial. While exploratory, the analysis indicates that treatment with extended–release niacin was associated with significantly increased rates of certain serious adverse events, as well as increased rates of dose reductions or drug discontinuation related in most cases to known side effects of niacin.
Axio served as the Data Coordinating Center (DCC) for AIM–HIGH, a large multi–center clinical trial sponsored by the NHLBI with additional support from Abbott Laboratories. Ruth McBride, Scientific Director at Axio, served as the Co–Director for the AIM–HIGH DCC. The original trial results were published in the New England Journal of Medicine in December 2011
For more information about the AIM–HIGH Trial results, please visit Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy.
For more information about the Letter to the Editor, please visit Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial.
ABOUT AXIO RESEARCH (www.axioresearch.com)
Founded by an internationally recognized group of biostatisticians in 1979, Axio Research has over 30 years of experience supporting pharmaceutical and biotechnology companies. Axio services range from providing data management, biostatisticial and DMC support to medical writing, statistical report writing, clinical event adjudication and custom web-based data collection tools. Axio staff experience includes working on projects ranging from small data management projects to DMC report generation for complex multi-center studies with hundreds of sites and thousands of patients.
The Axio Research is headquartered in Seattle, WA.
